COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes

doi:10.3748/wjg.v29.i7.1123

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3871)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

153

WORD

HTML

1973

Figures (1-1)

463

Sum=2648

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

152

Download

392

Sum=544

Publishing Process of This Article

Item

Count

Browse

198

Download

481

Sum=679

Feb 21, 2023 (publication date) through May 7, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Feb 21, 2023; 29(7): 1123-1130
Published online Feb 21, 2023. doi: 10.3748/wjg.v29.i7.1123

Open in New Tab Full Size Figure Download Figure

Figure 1 Summary of coronavirus disease 2019-induced liver dysfunction. MAFLD: Metabolic-associated fatty liver disease; AILD: Autoimmune liver diseases; COVID-19: Coronavirus disease 2019; ALT: Alanine transaminase; ULN: Upper limit of normal; AST: Aspartate transaminase; PICU: Pediatric intensive care; CLD: Chronic liver disease; HELLP: Hemolysis, elevated liver enzymes and low platelet; MISC: Multisystem inflammatory syndrome of children.

Citation: Said ZNA, El Habashy SA, Zaky S, ESCMID Study Group for Viral Hepatitis. COVID-19-induced transaminitis and hyperbilirubinemia: Presentation and outcomes. World J Gastroenterol 2023; 29(7): 1123-1130
URL: https://www.wjgnet.com/1007-9327/full/v29/i7/1123.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i7.1123